Posted by Michael Wonder on 25 Sep 2019
'Xtandi emerges as convenient treatment option for prostate cancer patients'
25 September 2019 - Astellas Korea is strengthening its position in the local prostate cancer market with Xtandi, a hormone therapy for prostate cancer, armed with various insurance benefits and indications for patients, the company said Tuesday.
The company won differential reimbursement for the drug in treating mCRPC as a first-line treatment on May 20. The new insurance plan resulted in the drug receiving reimbursement as both the first and second-line treatment for treating mCRPC and reduced the financial cost for patients who use Xtandi as a first-line treatment, by about 30%.
